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Genome-wide association studiesiated with complex diseases in humans are believed to have a small impact on
risk. With traditional candidate gene/pathway approaches several associations with disease risk could be
identiﬁed. However, now that genome-wide association studies are feasible, the question arises if there is
still a need for these approaches. By using HapMap data, we evaluated to which extent commercially
available microarrays cover, through linkage disequilibrium, all currently known genes and biological
processes in different populations. Furthermore, we estimated the power to detect an association with any
speciﬁc SNP. Our study shows that coverage of individual genes and pathways by current commercial
genotyping platforms is satisfactory for the vast majority of RefSeq gene regions. However, depending on the
gene or the population, there may still be a need for candidate gene approaches, especially when looking at
polymorphisms with low allele frequencies.
© 2009 Elsevier Inc. All rights reserved.IntroductionHistorically, association studies to detect alleles conferring
increased or decreased risk to common diseases with a complex
genetic risk component have employedmarkers in candidate genes, or
in all the genes belonging to a biological pathway or having a similar
biological function. The success of this approach depends upon the
correct choice ofwhich genes/pathways to study. Therefore, an a priori
hypothesis about biological function is required, which is exposed to
the risk of arbitrariness.
A more comprehensive and unbiased approach is to employ
markers encompassing the entire genome [1]. High-throughput
genotyping platforms have driven down the costs of genotyping
studies on a genome-wide scale. Several genome-wide association
studies (GWAS) for complex diseases have recently been completed,
as reviewed in Manolio et al. [2]. A key aspect in the efﬁciency of
GWAS is the notion of “indirect association,” where only a subset of
SNPs are collected to serve as proxies for the uncollected SNPs, taking
advantage of the linkage disequilibrium (LD) between SNPs.
The question thus arises, whether it is still sensible to perform
studies based on candidate genes/pathways when it is possible to
study the whole genome. Instead of setting up a new study, one could
simply look up the results for the candidate gene(s) of choice, if a
GWAS has already been completed on the endpoint under investiga-
tion. This would only be true if the coverage of the gene(s) in a GWASll rights reserved.is as good as what can be achieved with a more targeted approach. Of
course, this applies only to common diseases that, owing to their
frequency in the population, justify the cost of a GWAS. It is unlikely
that GWAS will be performed for rarer diseases, even those having a
strong genetic component, which can be studied more successfully by
approaches based on linkage analysis.
Previous reports have compared the coverage of whole genome
microarrays [1,3–7]. However, the results of these studies show the
coverage in terms of the whole genome, thus they do not provide a
complete answer to our question. In contrast to these approaches, we
concentrate on the coverage of gene regions. Using empirical geno-
type data from the International HapMap Project (http://www.
hapmap.org), we evaluate the extent to which two genotyping
platforms (Affymetrix 500K Human Mapping Array and Illumina
HumanHap 550 BeadChip) capture possible causative SNPs in each of
the genes in the RefSeq series, which is a good approximation for all
the genes in the human genome. To better determine the utility of the
platforms, we also estimated the power to ﬁnd an associated allele.
Methods
Bulk genotype and frequency data from NCBI Build 36 were down-
loaded for 270 HapMap individuals (http://hapmap.org/downloads/
index.html.en). The samples are separated in three ethnic groups: YRI
(90 individuals, 30 trios, from Yoruba of Ibadan, Nigeria), ASI (90
unrelated individuals from Japan, Tokyo and China, Beijing), and CEU
(90 U.S. residents, 30 trios, with Northern and Western European
ancestry). We selected SNPs that are located within RefSeq genes
Table 1
Coverage of common SNPs in gene regions
Sample set ASI CEU YRI
Gene_SNPs 795,832 849,474 945,335
Estimated Tag_SNPs 236,599 251,762 461,558
Platform Affy Illu Affy Illu Affy Illu
SNPs used to
cover Gene_SNPs
171,226 222,177 179,042 238,587 214,386 245,590
Average r2 0.82 0.92 0.82 0.94 0.67 0.75
Average powerdom 96.4% 98.1% 96.4% 98.7% 92.2% 93.5%
Average powerrec 60.3% 63.5% 59.9% 63.5% 51.6% 55.3%
416 S. Wilkening et al. / Genomics 93 (2009) 415–419(http://www.ncbi.nlm.nih.gov/RefSeq/), including 5 kb up- and
down-stream of each gene, with minor allele frequencies
(MAFs)≥0.05. HapMap genotypes from the Mapping 500K Assay
(Affymetrix) were obtained from http://www.affymetrix.com. Geno-
types from the Hap550 BeadChip (Illumina)were ﬁltered from the bulk
HapMapdata.We considered a set of tagging SNPs for a given gene to be
optimalwhen it achieved a coverage of the existingHapMap SNPs in the
gene region of at least 80% (r2N0.8). We obtained lists of tagging SNPs
with this criterion by using the Tagger Server (http://www.broad.mit.
edu/mpg/tagger/server.html) for NCBI Build 35. The maximum
distance for tagging SNPs was set to 500 kb. To estimate the number
of tagging SNPs that are needed to capture all SNPs in gene regionswith
MAF≥0.05 of NCBI Build 36, we added the fraction of non-overlapping
SNPs (about 7%) to the tagging SNPs from NCBI Build 35.
To specify to which extent SNPs in gene regions are covered by
SNPs of either platform, we used the LdCompare software [4]. This
software allows ﬁnding the SNP with the highest LD to a given SNP
within a given window of base pairs (bp) in a single- or multi-marker
mode [4]. The window size was set to 500,000 bp for single-marker
coverage and 100,000 bp for multi-marker coverage (using 500 kb
would result in inclusion of a larger number of SNPs, but computation
time scales up exponentially with the number of SNPs included,
therefore it would not have been practically feasible to work with a
500 kb window). SNPs on the microarrays were only excluded when
MAF was b0.01. To calculate multi-marker coverage with LdCompare,
phased haplotypes are required as input. For Illumina SNPs (Illu_SNPs)
and SNPs in gene regions (Gene_SNPs), phased haplotypes were
obtained from HapMap. For Affymetrix SNPs (Affy_SNPs), phased
haplotypes were estimated from genotypes using fastPHASE 1.2 [8].
Microsoft Access macros were used to create “ped” and “info” ﬁles
(for LdCompare) and for power calculation. To estimate the power to
detect an SNP of interest by one or more SNPs on the microarray, we
used the approximation given in Gart et al. [9]. The power was esti-
mated assuming penetrances of either a recessive or a dominant
model and a type I error of 0.05. For general power calculations, we set
the sample size to 1000 cases and 1000 controls and assumed an odds
ratio (OR) of 1.5 for the causative allele (referring always to the minor
allele). We also studied average power with varying numbers of case-
control pairs (from 500 to 10,000), varying ORs (from 1.1 to 2.0) and
MAFs (from 0.05 to 0.50) (see Supplementary ﬁgures 1–3). In the
power calculation, LDwas taken into account bymeans of the effective
sample size (the product of sample size and r2). This approach has
been described as the cumulative r2 adjusted power by Jorgenson
and Witte [10].
In order to classify genes into pathways, a list of biological
processes and correlated genes was downloaded from PANTHER
(www.pantherdb.org) (see Supplementary table 1).
Deﬁnitions
• YRI: 90 HapMap individuals of Yoruban origin.
• ASI: 90 HapMap individuals of Asian (Chinese and Japanese) origin.
• CEU: 90 HapMap individuals of Caucasian origin.
• Gene_SNPs: Complete set of common (MAF≥0.05) SNPs mapping
to gene regions of 17,848 RefSeq genes. Gene regions were deﬁned
as genomic sequence spanning from 5 kb upstream of the beginning
of the ﬁrst known exon to 5 kb downstream of the last known exon
of the gene.
• Tag_SNPs: Subgroup of Gene_SNPs that tags them with r2≥0.8
using a pairwise tagging algorithm. This is the “gold standard”
tagging set, deﬁned independently of genotyping platforms.
• Affy_SNPs: Set of SNPs included in the Affymetrix Mapping 500K
Array which map to the gene regions (deﬁned as above) of 17,848
RefSeq genes.
• Illu_SNPs: Set of SNPs included in the Illumina Hap550K BeadChip
which map to the gene regions (deﬁned as above) of 17,848 RefSeq
genes.Results
In order to answer the questionwhether it still makes sense to plan
candidate gene/pathway studies when a growing number of GWAS
are published, we studied the coverage of the 17,848 best-deﬁned
genes in the human genome (those included in the RefSeq catalog). To
this end, we used the Tagger algorithm to obtain the Tag_SNPs set,
which is our gold standard, i.e. the set of tagging SNPs for each gene
that one would select when planning a candidate gene study,
independently of the genotyping platform to be used. To capture all
Gene_SNPs with an r2N0.8 (pairwise tagging), one would need
236,599 tagging SNPs for ASI, 251,762 for CEU, and 461,558 for YRI.
We then benchmarked the performance of the two leading
commercial products for GWAS against this gold standard in terms
of coverage and power.
Gene coverage
From 17,848 gene regions, 780 (4.4%) had no annotated SNP with
MAF≥0.05 in one ormore population(s) (Supplementary table 2). For
the other genes, the coverage offered by the commercial arrays ranged
from satisfactory to good: large percentages of genes had a coverage
equal or greater than the commonly used gold standard (over 80% of
SNPs captured with r2N0.8), and only small proportions of genes had
a coverage much lower than that. In CEU for example, the proportion
of genes having an SNP coverage of 80% and higher (r2N0.8) was 35%
by Affy_SNPs and 80% by Illu_SNPs. From 17,304 genes in CEU with at
least one Gene_SNP, 669 genes were poorly covered (b10% of SNPs
with r2N0.8) by Affy_SNPs, but were well covered (N80% of SNPs with
r2N0.8) by Illu_SNPs (Supplementary table 3). Most of these genes
(71%) had less than 10 Gene_SNPs. The gene with most Gene_SNPs
(n=49) in this subset was NFAM1 (NFAT activating proteinwith ITAM
motif 1). On the other hand, 19 genes were well covered by Affy_SNPs
in CEU but not by Illu_SNPs. From these, the gene MRGPRX1 (MAS-
related G-protein coupled receptor member X1) was the one
with most (n=26) Gene_SNPs. For gene-coverage in ASI and YRI
see Supplementary tables 4 and 5.
In terms of power to detect association, the part of genes with high
power (N80% in 80% of the Gene_SNPs) was only 10% (dominant) and
2% (recessive) higher for Illu_SNPs compared to Affy_SNPs.
Biological process coverage
Recognizing that many candidate gene studies nowadays are
rather candidate pathway studies, we aimed at grouping the RefSeq
genes into pathways, and at comparing the coverage and power
offered by the commercial platforms for GWAS for each pathway. From
17,848 genes, 11,905 could be assigned to one or more of the 226
categories of biological processes as classiﬁed in the PANTHER
database. We used these biological processes as surrogates of
pathways. Not surprisingly, nearly all pathways were found to be
adequately covered by the commercial arrays (Supplementary tables
6–8). The biological processes that were among the 10 worst covered
Fig. 1. Coverage of Gene_SNPs (=all SNPs in RefSeq gene regions from HapMap) by 500K platforms (Affymetrix and Illumina) in different populations (ASI, CEU, YRI) displayed in
terms of LD (A) and power (B) to detect a dominantly (dom) or recessively (rec) acting SNPs. For the power calculation Tag_SNPs were included as well.
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populations were “growth factor homeostasis” (7 genes) and “taste”
(6 genes). “NO mediated signal transduction” (9 genes) and
“polyphosphate biosynthesis” (3 genes) were among the 10 worst
covered biological processes in two populations, respectively. The
biggest difference between both platforms for the coverage of a
biological process with more than 7 genes was “sulfur redox
metabolism” (18 genes) in all populations. In CEU, the average r2 for
this biological process was 0.91 for Illu_SNPs and 0.66 for Affy_SNPs.
Only in YRI, we found two biological processes, amylase (2 genes) and
chemosensory perception (2 genes), to have a signiﬁcantly higher
coverage by Affy_SNPs than by Illu_SNPs.
Affymetrix vs. Illumina
In general, Illu_SNPs showed a better coverage of Gene_SNPs than
Affy_SNPs (Table 1). From over 500,000 SNPs in both platforms, less
than half of the SNPs laywithin 5 kb of a gene and are linked by r2N0.8
with a Gene_SNP.
In Fig. 1, we show the percentage of Gene_SNPs covered by an
r2N0.8 (Fig. 1A) and with a power N80% (Fig. 1B) to detect a true
association. The power did not differ much between the two geno-
typing platforms, but strongly depended on the type of assumed
association (dominant or recessive). The average r2 of Illu_SNPs and
Affy_SNPs was slightly lower to capture Gene_SNPs of lower allele
frequencies, as shown for CEU in Fig. 2. To directly compare both
platforms, we also calculated the coverage of Illu_SNPs by Affy_SNPs
and vice versa, including all SNPs with MAF≥0.01. The average r2 ofFig. 2. Coverage of Gene_SNPs by different SNP sets (Tag_SNPs=reference set of
tagging SNPs, Affy_SNPs=SNPs from Affymetrix 500K and Illu_SNPs=SNPs from
Illumina Hap550) at different allele frequencies.Illu_SNPs covered by Affy_SNPs was 0.74 and 0.89 for Affy_SNPs
covered by Illu_SNPs.
The power to detect an associated SNP by another SNP signiﬁcantly
depends on the LD between the SNPs, the frequency of the associated
SNP, and the association model as shown in Fig. 3. How the power
differs between Affy_SNPs and Illu_SNPs according to association
model, MAF, OR, and sample size is shown for CEU samples in
Supplementary ﬁgures 1–3.
The coverage varied between the chromosomes, with chromosome
19 being the worst and chromosomes 2, 5, and 6 being among the
best-covered chromosomes for both platforms in all populations. In
CEU, the average r2 ranged from 0.90 to 0.95 for Illu_SNPs and 0.68 to
0.84 for Affy_SNPs (Supplementary table 9).
Multimarker coverage
To estimate the improvement of Gene_SNP coverage by the use of
multiple marker haplotypes (i.e. performing the selection of tagging
SNPs based on the use of multimarkers prediction, instead of relying
exclusively on pairwise LD), we calculated the coverage of all
Gene_SNPs on chromosome 21 by the use of one, two, or three
markers. While for the Affy_SNPs we found a substantial improve-
ment, for Illu_SNPs the improvement was very small (Fig. 4). In terms
of power, the difference between the two platforms as well as the gain
of multimarker usage was minimal (Supplementary Fig. 4). On the
other hand, one can decrease the number of haplotype tagging SNPs
needed to cover Gene_SNPs while maintaining a stable coverage
(r2≥0.8). 10,891 Gene_SNPs on chromosome 21 can be tagged by
3350 SNPs (mean r2 0.962) using one-marker and by 2801 SNPs
(mean r2 0.955) using multi-marker haplotypes (–16%).Fig. 3. Correlation between power and r2 at minor allele frequencies of 10, 20, 30, 40 and
50%. The graph shows dominantly (continuous lines) and recessively (dashed lines)
acting SNPs for a given OR of 1.5 and a sample size of 1000 cases and 1000 controls.
Fig. 4. Percentage of Gene_SNPs covered with an r2N0.8 by Affy_SNPs and Illu_SNPs
using 1, 2, or 3 SNP haplotypes.
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With close to 1 million Gene_SNPs, the YRI population had the
highest SNP density (Table 1). In general, there were more Gene_SNPs
with low allele frequencies than with high allele frequencies. This
effect was more pronounced in the YRI than in the other populations
(Supplementary Fig. 5). Comparing CEU and YRI, we found 159 genes
that had at least one Gene_SNP in YRI but no Gene_SNP in CEU. The
gene ZNF510 on chromosome 9 for example, had a total of 47
Gene_SNPs in YRI, but none in CEU (Supplementary table 2).
Discussion
Our study shows that coverage of individual genes and pathways
by both commercial products, as measured with our criteria (r2N0.8,
MAF≥0.05) is satisfactory for the vast majority of RefSeq gene
regions. We have provided detailed data on the coverage of each
RefSeq gene in the three populations considered (Supplementary
tables 3–5), which can be checked for verifying how well a given gene
of interest is covered by the available genome-wide arrays.
We have considered two speciﬁc commercial products, the
Affymetrix 500K Human Mapping Array and Illumina HumanHap
550 BeadChip, because the vast majority of GWAS published so far or
in the process of being published have been performed with one of
these products. These two arrays are the de facto standard for GWAS.
Both companies have currently on the market new versions of
genotyping arrays, with larger numbers of SNPs. However, as we show
here (see Results and discussion below) that about 500,000 SNPs offer
a very good coverage for nearly all RefSeq genes, whatever improve-
ment is offered by larger arrays is not likely to alter signiﬁcantly the
picture.
In general, Illu_SNPs showed a higher coverage of the Gene_SNPs
than Affy_SNPs. This was not surprising, because Affy_SNPs have been
selected primarily on the basis of technical quality and thus represent a
quasi-random set of SNPs. In contrast, SNPs on the Illumina product
were selected using a pairwise correlation-based algorithm applied to
genotype data of HapMap Phase I SNPs in the CEU panel [11].
Furthermore, 14,069 Affy_SNPs were shown to be monomorphic in a
European population with 1644 individuals [12]. However, comparing
the power of the two platforms to detect a possible causative SNP, the
difference between the two platforms becomes less signiﬁcant (Fig.1B).
Chromosome 19 was found to be the chromosomewith the lowest
overall Gene_SNP coverage in all populations. This can be explained by
the fact that chromosome 19 has also the highest gene density of all
human chromosomes, more than double the genome-wide average
[13,14]. Recombination statistics for chromosome 19 are similar to
other human chromosomes [15]. Compared to previously published
data [3,5] (analyzing the SNP set from the entire genome), the
percentage of Gene_SNPs covered with an r2N0.8 was higher in our
study. This difference was highest for Illu_SNPs in the YRI, where theGene_SNP coverage was 58% and 48% for a genome wide SNP set [5].
This suggests that many of the poorly covered SNPs in YRI are not
located in gene regions. It has to be noticed that the coverage distance
(200 kb Magi et al. and 500 kb our study) and the NCBI Builds (34
Magi et al. and 36 our study) were different in both studies.
For the power calculation, we have chosen the recessive and the
dominant model, because these deﬁne the extremes in terms of the
power to detect a given SNP. In the recessive model, only homozygous
individuals for the disease-associated allele show the phenotype, in a
dominant model all carriers of the disease allele show the phenotype.
To calculate the power in association studies, one would normally
adjust for multiple testing. In our study, we present values of power
calculated assuming a type I error of 0.05, thus without adjustment for
multiple testing. The adjustment one would perform would be
drastically different in a GWAS or in a candidate gene study, either
by Bonferroni correction (which typically gives signiﬁcance thresh-
olds of p=10−7 for GWAS and of p=10−3–10−4 for candidate gene
studies) or by Bayesian methods, such as FPRP [16] or BFDP [17],
where the prior probabilities are much higher for SNPs in candidate
genes than for SNPs in a genome-wide set.
Multi-marker methods have been shown to improve the coverage
of an SNP by the combination of two or more SNPs [4,6,7]. This
method can be used to reduce the number of SNPs needed for a high
coverage or improve the coverage of SNPs in an existing platform.
Our results suggest that the coverage of a suboptimal SNP set can
substantially be improved by multi-marker usage, but the improve-
ment for the power to detect a recessive or dominant allele remains
relatively small.
Considering the huge differences between the three analyzed
populations, future genotyping platforms might be speciﬁcally gene-
rated for one or the other population. However, a platform that covers
most of the polymorphisms in the African population would most
likely cover well all other populations, too. Some genes are polymor-
phic only in the African population, such as the gene ZNF510 (zinc
ﬁnger protein 510).
In our study, we gave an estimation of the coverage of all known
genes at present, by using the RefSeq set of genes (n=17,848) as a
proxy. The HapMap database with over 4 million SNPs is the gold
standard for determining LD between SNPs. However, only a limited
number of individuals have been genotyped so far and there are still
unknown SNPs and genes. Other polymorphisms like copy number
variations can be captured only in a limited way by SNPs [18]. It has to
be pointed out that our study shows only how good the different
approaches are to cover variability represented in HapMap, and does
not address at all how good the representation is by HapMap of the
real variability in the genome (which could be suboptimal at least in
some regions. Some studies based on resequencing challenge the
representativeness of HapMap (e.g. [19,20]). Another limitation of our
study is that we have not included SNPs with low (b5%) MAF in the
Gene_SNPs set. On the other hand, GWAS are not designed to study
less frequent variants, and most candidate gene studies use the same
MAF threshold (although it has to be recognized that candidate gene
studies do allow for a more targeted selection of SNPs, including rare
ones and polymorphisms with known function).
In conclusion, most of the variability in gene regions is covered
well by the current 500K genotyping platforms. Ideally, one would
have access to raw results of a GWAS, where data are available for
the whole set of SNPs genotyped, such as those of the Cancer Genetic
Markers of Susceptibility (CGEMS) project (https://caintegrator.nci.
nih.gov/cgems/). The subset of SNPs of interest, covering the desired
genes/pathways, could then be reanalyzed, by using amultiple testing
adjustment appropriate for the number of SNPs under consideration.
If the complete dataset of a GWAS is not available, this approach
becomes less meaningful, as papers reporting on GWAS results usually
mention only SNPs that reach genome-wide signiﬁcance (pof asso-
ciation ≤10−7), thus there may be SNPs belonging to a gene of
419S. Wilkening et al. / Genomics 93 (2009) 415–419interest that are not mentioned but still reach signiﬁcance levels
sufﬁcient for a candidate gene study (p≤10−3–10−4).
Depending on the gene or the population, there may still be a need
to perform new genotyping for candidate gene studies, especially
when looking at polymorphisms with low allele frequencies.
Another situation where the candidate gene/region approach is
useful is the post-GWAS phase, when a few associations have been
convincingly demonstrated and exhaustive work has to be performed
to identify the actual causative variants. This work will include deep
resequencing of candidate regions and study of rare polymorphisms.
Finally, an important factor to consider is that the cost of geno-
typing for a GWAS is still at least an order of magnitude higher than
the cost to genotype several candidate genes. Therefore, if a GWAS in a
given disease has not yet been performed, or if detailed results from an
existing GWAS are not publicly available, it could still be cost-effective
to perform a candidate gene/pathway study.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ygeno.2008.12.011.
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